A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreductive Induction Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 10 May 2017
At a glance
- Drugs NTX 010 (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 28 Mar 2017 Status changed from active, no longer recruiting to discontinued, as interim analysis declared futility.
- 31 May 2013 Results of the pre-planned interim futility analysis presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 31 May 2013 Status changed from recruiting to active no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History